Overview

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium or high daily dose).

Phase:

Phase 2

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Olodaterol